ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today reported completion of patient recruitment of IMPLANT 4 Phase 3 clinical trial of its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing embryo transfer (ET) following assisted reproduction technology (ART), or in-vitro fertilization (IVF)

IMPLANT 4 is being conducted at 48 sites, in Europe, Canada and Russia, randomizing approximately 820 patients undergoing embryo transfer following IVF. Eligible women are receiving either a single oral 900 mg dose of nolasiban or placebo four hours prior to a Day 5 single embryo transfer (SET). Key efficacy endpoints of the IMPLANT 4 trial are the proportion of patients achieving ongoing pregnancy 10 weeks post embryo transfer (ET) and live birth rate (LBR), and follow-up will include 28-day neonatal assessment, as well as infant development assessment at 6 and 12 months post-birth.  Positive primary endpoint results for IMPLANT 4 in the fourth quarter of 2019 would confirm the prior positive IMPLANT 2 trial results, and allow ObsEva to proceed with a Marketing Authorization Application in Europe.

“We are very pleased by the completion of patient recruitment for the IMPLANT 4 trial, an important step toward bringing nolasiban to patients undergoing the demanding procedure of IVF, and improving their chances to take home a baby,” said Ernest Loumaye, co-founder and Chief Executive Officer of ObsEva “With a successful IMPLANT 4 outcome and planned MAA in Europe, ObsEva is evolving into a commercial company with a unique and innovative product that may not only help patients, but has the potential to lower associated healthcare costs.”

About Assisted Reproductive Technology (ART)

Infertility affects about 10 % of reproductive-aged couples, with more than 2 million ART treatments (including IVF and ICSI) performed worldwide each year. Currently 62% of fresh embryo transfers are performed on Day 5 and 30% on Day 3 in the United States (CDC report, 2016 data).

While the success of ART depends on multiple factors such as embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation.

Uterine contractions at the time of ET, as well as suboptimal thickness of the uterine wall and blood flow to the uterus, may impair the implantation of the embryo.

About Nolasiban

Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist with the potential to decrease uterine contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation, all of which may increase the chance of successful pregnancy and live-birth among patients undergoing ART. ObsEva licensed nolasiban from Merck KGaA, Darmstadt, Germany, in 2013 and retains worldwide, exclusive, commercial rights.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.